The Biosimilars Council

The Biosimilars Council applauds reintroduction of the bipartisan BIOSIM Act

April 23, 2021 by Chain Drug Review The Biosimilars Council Leading Headlines, Pharmacy

WASHINGTON — The Biosimilars Council, representing leading developers of biosimilar medicines, strongly supports the reintroduction, and encourages swift passage, of the bipartisan BIOSIM Act (HR 2815). This bill is an important step toward giving Americans greater access to lifesaving, affordable medicines. Christine Simmon, executive director of the Biosimilars Council, said, Every day, biosimilars help patients

FDA proposes suffix for biosimilar product names

August 31, 2015 by Chain Drug Review Academy of Managed Care Pharmacy, AMCP, Bertrand Liang, biologic drugs, biologic products, Biologics Prescribers Collaborative, biosimilar product names, biosimilars, Biosimilars Forum, Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, Edith Rosato, Food and Drug Administration, GPhA, Janet Woodcock, Karen Midthun, The Biosimilars Council Featured Articles, Leading Headlines, Pharmacy, Supplier News

WASHINGTON — Early feedback on the Food and Drug Administration’s proposal on naming conventions for biosimilars shows a mixed response. Late late week, the FDA published draft guidance recommending that reference biologic products and biosimilars have nonproprietary names that share a core drug substance name and an FDA-designated suffix unique for each product. For interchangeable